Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846888 | 1.00 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL5696092 | 0.94 | ALDH1A1 (0.39) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL5696091 | 0.94 | ALDH1A1 (0.39) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL14511230 | 0.94 | ALDH1A1 (0.39) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL14511226 | 0.92 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL1098026 | 0.92 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL1098024 | 0.92 | ALDH1A1 (0.36) | ALDH1A1GSTP1LMNABCHECYP2D6 | |
| SCHEMBL1096197 | 0.86 | BCHE (0.39) | ALDH1A1GSTP1BCHEMETAP2 | |
| SCHEMBL1097346 | 0.86 | BCHE (0.39) | ALDH1A1GSTP1BCHEMETAP2 | |
| SCHEMBL1096195 | 0.86 | BCHE (0.39) | ALDH1A1GSTP1BCHEMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334109-B1 | IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES | SANTARIS PHARMA AS (DK) | 2006-05-10 | — | — | EP | disclosed |
| US-6998484-B2 | Synthesis of purine locked nucleic acid analogues | SANTARIS PHARMA A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| US-20020086998-A1 | Synthesis of purine locked nucleic acid analogues | SANTARIS PHARMA A/S (DK) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086998-A1 | Synthesis of purine locked nucleic acid analogues | RNGTT, PNP, UNG | ALDH1A1 1637/4885GSTP1 3174/4885LMNA 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.